Skip to main content

Advertisement

SpringerLink
Log in

Cost of illness of medically treated benign prostatic hyperplasia in Hungary

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Objective

To perform a cost of illness study in lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH) in Hungary.

Methods

A multicentre, cross-sectional survey was carried out in 2014. BPH patients who had never undergone prostate surgery were recruited to the study. EQ-5D and the International Prostate Symptom Score (IPSS) were used to evaluate health status and disease severity. All resource utilisations related to BPH in the past 12 months were recorded. Cost analysis was performed from societal perspective.

Results

Overall, 246 patients were included with mean age of 70.6 (SD 8.1) years. Mean EQ-5D and IPSS were 0.85 (SD 0.19) and 12.8 (SD 6.3). Total annual per patient cost of BPH amounted to €876 (SD €1829). Distribution of the costs between direct medical, direct non-medical and indirect cost was 46, 31 and 23 %. High costs were related to informal care (€243), medications (€178) and private physician visits (€132). Patients missed from work on average 14 h/year and 20 h/year due to absenteeism and presenteeism. Clinical severity expressed in IPSS score was found the strongest predictor of higher total costs (r = 0.429, p < 0.001). Mean costs of mild, moderate and severe patients were €203, €754 and €2168, respectively.

Conclusions

To our knowledge, this is the first study in the literature that assessed indirect costs related to presenteeism in BPH. We found that costs of reduced productivity while working exceed costs of absence from work. As the retirement age is gradually increasing, the importance of presenteeism is getting more significant, especially in pursuit of sustainable employment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Parsons JK, Wilt TJ, Wang PY, Barrett-Connor E, Bauer DC, Marshall LM (2010) Progression of lower urinary tract symptoms in older men: a community based study. J Urol 183(5):1915–1920. doi:10.1016/j.juro.2010.01.026

    Article  PubMed Central  PubMed  Google Scholar 

  2. WHO Global Burden of Disease, DALY estimates, 2000–2012. http://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html. Accessed 07 Apr 2015

  3. Boncz I, Vajda R, Agoston I, Endrei D, Sebestyen A (2014) Changes in the health status of the population of Central and Eastern European countries between 1990 and 2010. Eur J Health Econ HEPAC 15(Suppl 1):S137–S141. doi:10.1007/s10198-014-0602-8

    Article  PubMed  Google Scholar 

  4. Speakman M, Kirby R, Doyle S, Ioannou C (2014) Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)—focus on the UK. BJU Int. doi:10.1111/bju.12745

    PubMed  Google Scholar 

  5. Rencz F (2012) A jóindulatú prosztata-megnagyobbodás egészség-gazdaságtani elemzése. Köz-Gazdaság 7(3):135–151

    Google Scholar 

  6. Saigal CS, Joyce G (2005) Economic costs of benign prostatic hyperplasia in the private sector. J Urol 173(4):1309–1313. doi:10.1097/01.ju.0000152318.79184.6f

    Article  PubMed  Google Scholar 

  7. Kirby RS, Kirby M, Fitzpatrick JM (2010) Benign prostatic hyperplasia: counting the cost of its management. BJU Int 105(7):901–902. doi:10.1111/j.1464-410X.2010.09274.x

    Article  PubMed  Google Scholar 

  8. Nickel JC (2006) The economics of medical therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. Curr Urol Rep 7(4):282–287

    Article  PubMed  Google Scholar 

  9. van Exel NJ, Koopmanschap MA, McDonnell J, Chapple CR, Berges R, Rutten FF (2006) Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six european countries: report of the TRIUMPH study. Eur Urol 49(1):92–102. doi:10.1016/j.eururo.2005.09.016

    Article  PubMed  Google Scholar 

  10. Gulacsi L, Rotar AM, Niewada M, Loblova O, Rencz F, Petrova G, Boncz I, Klazinga NS (2014) Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. Eur J Health Econ HEPAC 15(Suppl 1):13–25. doi:10.1007/s10198-014-0590-8

    Article  Google Scholar 

  11. EuroQol G (1990) EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16(3):199–208

    Article  Google Scholar 

  12. Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35(11):1095–1108

    Article  CAS  PubMed  Google Scholar 

  13. Barry MJ, Fowler FJ Jr, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT (1992) The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148(5):1549–1557

    CAS  PubMed  Google Scholar 

  14. Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 4(5):353–365

    Article  CAS  PubMed  Google Scholar 

  15. National Health Insurance Fund Administration (2014) Diagnosis-related groups (DRG) classification scheme 5.0. http://www.gyogyinfok.hu/magyar/fekvo/hbcs50/konyv/aktualis/10_2012_NEFMI_fekvo_20140501.zip. Accessed 03 Feb 2015

  16. National Health Insurance Fund Administration of Hungary (2014) International Classification of Procedures in Medicine codes. http://www.gyogyinfok.hu/szabalykonyv/index.asp?verzio=143&mid=0. Accessed 20 Feb 2015

  17. National Health Insurance Fund Administration (2014) National price list of pharmaceuticals. http://www.oep.hu//data/cms1003869/PUPHA_20141201_v2_kozos.zip. Accessed 19 Jan 2015

  18. National Health Insurance Fund Administration of Hungary. Official price list for the reimbursement of medical devices. http://sejk.oep.hu/content.php?s=portalmain&portallang=hu. Accessed 16 Feb 2015

  19. Hungarian Central Statistical Office (2014) Average monthly net earnings of employees. http://www.ksh.hu/docs/hun/xstadat/xstadat_evkozi/e_qli030.html. Accessed 08 Mar 2015

  20. Braakman-Jansen LM, Taal E, Kuper IH, van de Laar MA (2012) Productivity loss due to absenteeism and presenteeism by different instruments in patients with RA and subjects without RA. Rheumatology (Oxford) 51(2):354–361. doi:10.1093/rheumatology/ker371

    Article  Google Scholar 

  21. Hungarian Central Statistical Office (2014) Average monthly gross earnings of employees. www.ksh.hu/docs/hun/xstadat/xstadat_evkozi/e_qli029.html. Accessed 03 Aug 2015

  22. Szende A, Nemeth R (2003) Health-related quality of life of the Hungarian population. Orv Hetil 144(34):1667–1674

    PubMed  Google Scholar 

  23. Castro-Diaz D, Diaz-Cuervo H, Perez M (2013) Benign prostatic hyperplasia and its treatment: impact on quality of life and sexual function. Actas Urol Esp 37(4):233–241. doi:10.1016/j.acuro.2012.08.001

    Article  CAS  PubMed  Google Scholar 

  24. Fourcade RO, Lacoin F, Roupret M, Slama A, Le Fur C, Michel E, Sitbon A, Cotte FE (2012) Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia. World J Urol 30(3):419–426. doi:10.1007/s00345-011-0756-2

    Article  PubMed Central  PubMed  Google Scholar 

  25. Song HJ, Han MA, Kang HC, Park KS, Kim KS, Kim MK, Kang J, Park EO, Hyun MY, Kim CS (2012) Impact of lower urinary tract symptoms and depression on health-related quality of life in older adults. Int Neurourol J 16(3):132–138. doi:10.5213/inj.2012.16.3.132

    Article  PubMed Central  PubMed  Google Scholar 

  26. Trueman P, Hood SC, Nayak US, Mrazek MF (1999) Prevalence of lower urinary tract symptoms and self-reported diagnosed ‘benign prostatic hyperplasia’, and their effect on quality of life in a community-based survey of men in the UK. BJU Int 83(4):410–415

    Article  CAS  PubMed  Google Scholar 

  27. Balogh O, Brodszky V, Gulacsi L, Heredi E, Herszenyi K, Jokai H, Karpati S, Baji P, Remenyik E, Szegedi A, Hollo P (2014) Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres. Eur J Health Econ HEPAC 15(Suppl 1):S101–S109. doi:10.1007/s10198-014-0599-z

    Article  PubMed  Google Scholar 

  28. Rencz F, Brodszky V, Péntek M, Balogh O, Remenyik É, Szegedi A, Holló P, Kárpáti S, Jókai H, Herszényi K, Herédi E, Szántó S, Gulácsi L (2014) Disease burden of psoriasis associated with psoriatic arthritis in Hungary. Orv Hetil 155(48):1913–1921

    Article  PubMed  Google Scholar 

  29. Pentek M, Bereczki D, Gulacsi L, Mikudina B, Aranyi Z, Juhos V, Baji P, Brodszky V (2013) Survey of adults living with epilepsy in Hungary: health-related quality of life and costs. Ideggyogyaszati szemle 66(7–8):251–261

    PubMed  Google Scholar 

  30. Tamas G, Gulacsi L, Bereczki D, Baji P, Takats A, Brodszky V, Pentek M (2014) Quality of life and costs in Parkinson’s disease: a cross sectional study in Hungary. PLoS One 9(9):e107704. doi:10.1371/journal.pone.0107704

    Article  PubMed Central  PubMed  Google Scholar 

  31. Hungarian guideline for pharmacists and general practitioners on the management of BPH (2012). http://gyogygond.hu/sites/default/files/bph/GYGSZB_BPH_Gygyogysz_es_haziorv_iranyelv_2012.pdf. Accessed 04 July 2015

  32. OECD Statistics Database. Health expenditure. http://stats.oecd.org/index.aspx?DataSetCode=SHA. Accessed 12 Apr 2015

  33. Bellinger AS, Elliott SP, Yang L, Wei JT, Saigal CS, Smith A, Wilt TJ, Strope SA (2012) Changes in initial expenditures for benign prostatic hyperplasia evaluation in the Medicare population: a comparison to overall Medicare inflation. J Urol 187(5):1739–1746. doi:10.1016/j.juro.2011.12.079

    Article  PubMed Central  PubMed  Google Scholar 

  34. Carballido J, Ruiz-Cerda JL, Unda M, Baena V, Campoy P, Manasanch J, Slof J (2008) Economic evaluation of medical treatment of benign prostatic hyperplasia (BPH) in the specialised care setting in Spain. Application to the cost-effectiveness of two drugs frequently used in its treatment. Actas Urol Esp 32(9):916–925

    Article  CAS  PubMed  Google Scholar 

  35. Cozar JM, Huerta A (2013) Care management of patients with benign prostatic hyperplasia in Spain. Actas Urol Esp 37(1):60–61. doi:10.1016/j.acuro.2012.07.002

    CAS  PubMed  Google Scholar 

  36. DiSantostefano RL, Biddle AK, Lavelle JP (2006) An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia. BJU Int 97(5):1007–1016. doi:10.1111/j.1464-410X.2005.06089.x

    Article  PubMed  Google Scholar 

  37. Johansen TE, Istad JA (2007) Long-term cost analysis of treatment options for benign prostatic hyperplasia in Norway. Scand J Urol Nephrol 41(2):124–131. doi:10.1080/00365590600911266

    Article  PubMed  Google Scholar 

  38. Saigal CS, Movassaghi M, Pace J, Joyce G (2007) Economic evaluation of treatment strategies for benign prostatic hyperplasia–is medical therapy more costly in the long run? J Urol 177(4):1463–1467. doi:10.1016/j.juro.2006.11.083

    Article  PubMed  Google Scholar 

  39. Strope SA, Elliott SP, Smith A, Wei JT, Wilt TJ, Saigal CS (2011) Urologist practice styles in the initial evaluation of elderly men with benign prostatic hyperplasia. Urology 77(3):535–540. doi:10.1016/j.urology.2010.07.485

    Article  PubMed Central  PubMed  Google Scholar 

  40. Taub DA, Wei JT (2006) The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States. Curr Urol Rep 7(4):272–281

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standard

The study was carried out in accordance with the ethical standards of the national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Ethical approval (reference number: 24197-2/2014/EKU) was obtained from the Hungarian Medical Research Council. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Author information

Author notes

    Authors and Affiliations

    1. Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, Budapest, 1093, Hungary

      Fanni Rencz, Ágnes Kovács, Valentin Brodszky & László Gulácsi

    2. Semmelweis University Doctoral School of Clinical Medicine, Üllői út 26, Budapest, 1085, Hungary

      Fanni Rencz

    3. Astellas Pharma Hungary, Csörsz u. 49-51, Budapest, 1124, Hungary

      Ágnes Kovács

    4. Department of Urology, Jahn Ferenc South-Pest Hospital and Clinic, Köves utca 1, Budapest, 1204, Hungary

      Zalán Németh

    5. Department of Urology, Saint Borbala Hospital of Tatabánya, Dózsa György út 77, Tatabanya, 2800, Hungary

      Gábor János Nagy

    6. Urologic Ambulance, Szentgotthárd Clinic, Hunyadi J. u. 18, Szentgotthárd, 9970, Hungary

      János Nagy

    7. Department of Urology and Surgery, Péterfy Sándor Hospital, Péterfy Sándor u. 8-20, Budapest, 1074, Hungary

      István Buzogány

    8. Department of Urology, Bajcsy-Zsilinszky Hospital and Clinic, Maglódi út 89-91, Budapest, 1106, Hungary

      Géza Böszörményi-Nagy

    9. Semmelweis University Department of Urology, Üllői út 78/b, Budapest, 1082, Hungary

      Attila Majoros & Péter Nyirády

    Authors
    1. Fanni Rencz
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Ágnes Kovács
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Valentin Brodszky
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. László Gulácsi
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Zalán Németh
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Gábor János Nagy
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. János Nagy
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. István Buzogány
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Géza Böszörményi-Nagy
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. Attila Majoros
      View author publications

      You can also search for this author in PubMed Google Scholar

    11. Péter Nyirády
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to László Gulácsi.

    Additional information

    Attila Majoros and Péter Nyirády have contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Rencz, F., Kovács, Á., Brodszky, V. et al. Cost of illness of medically treated benign prostatic hyperplasia in Hungary. Int Urol Nephrol 47, 1241–1249 (2015). https://doi.org/10.1007/s11255-015-1028-7

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s11255-015-1028-7

    Keywords

    Search

    Navigation